These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 28988441)
1. A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor. Estes C; Sadoughi B; Coleman R; Sarva H; Mauer E; Sulica L Laryngoscope; 2018 Feb; 128(2):437-446. PubMed ID: 28988441 [TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor. Justicz N; Hapner ER; Josephs JS; Boone BC; Jinnah HA; Johns MM Laryngoscope; 2016 Jan; 126(1):113-7. PubMed ID: 26198384 [TBL] [Abstract][Full Text] [Related]
3. Treatment of Patients with Vocal Fold Atrophy and Comorbid Essential Voice Tremor: Long-Term Injection Augmentation Outcomes After Successful Diagnostic Vocal Fold Injection Augmentation. Van Doren M; Faudoa E; Carroll TL J Voice; 2020 May; 34(3):471-476. PubMed ID: 30503608 [TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of essential voice tremor: a study of 34 cases. Sulica L; Louis ED Laryngoscope; 2010 Mar; 120(3):516-28. PubMed ID: 20066728 [TBL] [Abstract][Full Text] [Related]
6. A new paradigm for the management of essential vocal tremor with botulinum toxin. Gurey LE; Sinclair CF; Blitzer A Laryngoscope; 2013 Oct; 123(10):2497-501. PubMed ID: 23553653 [TBL] [Abstract][Full Text] [Related]
12. The treatment of essential voice tremor with botulinum toxin A: a longitudinal case report. Warrick P; Dromey C; Irish J; Durkin L J Voice; 2000 Sep; 14(3):410-21. PubMed ID: 11021508 [TBL] [Abstract][Full Text] [Related]
13. Assessment of Patients Receiving Short-Interval Botulinum Toxin Chemodenervation Treatment for Laryngeal Dystonia and Essential Tremor of the Vocal Tract. Lagos-Villaseca A; Bhatt NK; Abdolhosseini P; Quinonez L; Paoletti MF; Gochman G; Johns MM; Rosen CA; Kao TC; Meyer TK JAMA Otolaryngol Head Neck Surg; 2023 Jul; 149(7):615-620. PubMed ID: 37227721 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Essential Vocal Tremor: A Scoping Review of Evidence-Based Therapeutic Modalities. Khoury S; Randall DR J Voice; 2024 Jul; 38(4):922-930. PubMed ID: 35022154 [TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Warrick P; Dromey C; Irish JC; Durkin L; Pakiam A; Lang A Laryngoscope; 2000 Aug; 110(8):1366-74. PubMed ID: 10942143 [TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section. Sulica L; Blitzer A; Brin MF; Stewart CF Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116 [TBL] [Abstract][Full Text] [Related]
17. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin. Meyer TK; Hu A; Hillel AD Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277 [TBL] [Abstract][Full Text] [Related]
18. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia. Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575 [TBL] [Abstract][Full Text] [Related]
19. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor. Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335 [TBL] [Abstract][Full Text] [Related]